scholarly article | Q13442814 |
P50 | author | Rosa Fernandes | Q47503161 |
Frederico Teixeira | Q57903181 | ||
Jorge Oliveira | Q59675095 | ||
Edite Teixeira De Lemos | Q64190488 | ||
Flávio Reis | Q38545312 | ||
Helena Vala | Q47352510 | ||
P2093 | author name string | Cristina Mega | |
Edite Teixeira de Lemos | |||
Filipa Mascarenhas-Melo | |||
P2860 | cites work | Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 | Q27860575 |
Use and abuse of HOMA modeling | Q28263292 | ||
Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study | Q30320781 | ||
Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. | Q33215328 | ||
Progression of diabetic nephropathy. Insights from cell culture studies and animal models | Q33648914 | ||
Rodent models of nephropathy associated with type II diabetes. | Q33707059 | ||
Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat) | Q34003019 | ||
Obesity-related glomerulopathy: an emerging epidemic | Q34190647 | ||
Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice. | Q51382768 | ||
Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. | Q51497444 | ||
Trends in incidence of end-stage renal disease in Japan, 1983-2000: age-adjusted and age-specific rates by gender and cause. | Q54655646 | ||
Pathologic classification of diabetic nephropathy. | Q55052603 | ||
Evolution of metabolic and renal changes in the ZDF/Drt-fa rat model of type II diabetes | Q71534418 | ||
Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats | Q72324013 | ||
Studies of renal injury III: lipid-induced nephropathy in type II diabetes | Q73322118 | ||
Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats | Q73430341 | ||
Podocyte injury underlies the progression of focal segmental glomerulosclerosis in the fa/fa Zucker rat | Q74082999 | ||
The prevalence and management of cardiorenal risk factors in patients with diabetic nephropathy | Q79196433 | ||
Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs | Q79551083 | ||
Trends in incidence of treated end-stage renal disease, overall and by primary renal disease, in persons aged 20-64 years in Europe, Canada and the Asia-Pacific region, 1998-2002 | Q81095258 | ||
Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level | Q83572227 | ||
Pathological influence of obesity on renal structural changes in chronic kidney disease | Q84077100 | ||
Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes | Q84782119 | ||
Incretins: Clinical Perspectives, Relevance, and Applications for the Primary Care Physician in the Treatment of Patients With Type 2 Diabetes Mellitus | Q34374350 | ||
The biology of incretin hormones | Q34499706 | ||
Intrarenal oxidative stress and augmented angiotensinogen are precedent to renal injury in Zucker diabetic fatty rats | Q35161497 | ||
Lipids and diabetic nephropathy | Q36659493 | ||
Relation of low glomerular filtration rate to metabolic disorders in individuals without diabetes and with normoalbuminuria | Q36662078 | ||
Incretins and their role in the management of diabetes | Q36973100 | ||
Pathophysiology of diabetic nephropathy | Q37059936 | ||
Type 2 diabetes and oral antihyperglycemic drugs | Q37066136 | ||
Diabetes and chronic kidney disease: a complex combination | Q37139159 | ||
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes | Q37221770 | ||
The incretin system and its role in type 2 diabetes mellitus | Q37266863 | ||
Recent advances in the management of type 2 diabetes mellitus: a review. | Q37328847 | ||
The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions | Q37335669 | ||
Pathogenic perspectives for the role of inflammation in diabetic nephropathy. | Q37387708 | ||
Pathophysiology of diabetic nephropathy: involvement of multifaceted signalling mechanism | Q37520505 | ||
Vascular disease in the metabolic syndrome: do we need to target the microcirculation to treat large vessel disease? | Q37538324 | ||
Sitagliptin: a review of its use in the management of type 2 diabetes mellitus | Q37703202 | ||
Oxidative stress in early diabetic nephropathy: fueling the fire | Q37820092 | ||
Diabetic nephropathy in 2010: Alleviating the burden of diabetic nephropathy | Q37833489 | ||
Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats | Q40756554 | ||
Role of the renin angiotensin system in diabetic nephropathy | Q42723231 | ||
A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin) | Q43046185 | ||
Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent. | Q43262211 | ||
Renal glucose reabsorption during hypertonic glucose infusion in female streptozotocin-induced diabetic rats | Q43644419 | ||
Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats | Q43972544 | ||
Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis | Q44103908 | ||
Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. | Q45000524 | ||
Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen | Q45038702 | ||
Diabetes, the kidney, and cardiovascular risk. Foreword. | Q45959800 | ||
The factors for progression of the diabetic nephropathy: management and evolution | Q46095840 | ||
Angiotensin blockade and matrix synthesis by glomerular epithelial cells in high glucose: a further experimental insight into the pathophysiology of diabetic nephropathy. | Q46506887 | ||
Increased glomerular and extracellular malondialdehyde levels in patients and rats with diabetic nephropathy | Q46728417 | ||
A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. | Q46774459 | ||
Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule. | Q46852265 | ||
Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats | Q46975284 | ||
P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
P6216 | copyright status | copyrighted | Q50423863 |
P921 | main subject | diabetic nephropathy | Q1129105 |
type 2 diabetes | Q3025883 | ||
P304 | page(s) | 162092 | |
P577 | publication date | 2011-11-30 | |
P1433 | published in | Experimental Diabetes Research | Q26842719 |
P1476 | title | Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat) | |
P478 | volume | 2011 |